Abstract
Phase I and II enzymes are involved in the metabolism of endogenous reactive compounds as well as xenobiotics, including toxicants and drugs. Genotyping studies have established several drug metabolizing enzymes as markers for risk of drug hypersensitivity. However, other candidates are emerging that are involved in drug metabolism but also in the generation of danger or costimulatory signals. Enzymes such as aldo-keto reductases (AKR) and glutathione transferases (GST) metabolize prostaglandins and reactive aldehydes with proinflammatory activity, as well as drugs and/or their reactive metabolites. In addition, their metabolic activity can have important consequences for the cellular redox status, and impacts the inflammatory response as well as the balance of inflammatory mediators, which can modulate epigenetic factors and cooperate or interfere with drug-adduct formation. These enzymes are, in turn, targets for covalent modification and regulation by oxidative stress, inflammatory mediators, and drugs. Therefore, they constitute a platform for a complex set of interactions involving drug metabolism, protein haptenation, modulation of the inflammatory response, and/or generation of danger signals with implications in drug hypersensitivity reactions. Moreover, increasing evidence supports their involvement in allergic processes. Here, we will focus on GSTP1-1 and aldose reductase (AKR1B1) and provide a perspective for their involvement in drug hypersensitivity.
Introduction
Drug hypersensitivity reactions pose an important clinical problem. They reduce the therapeutic armamentarium and may entail great severity, being life threatening in some cases. These reactions are mediated by the activation of the immune system by drugs or their metabolites. This can occur through the direct interaction of the drug/metabolite with receptors from immune cells or by covalent attachment of the drug to endogenous proteins, in a process known as haptenation. It is often considered that drugs are too small structures to activate the immune system on their own, whereas haptenated proteins or peptides can fulfill this role and be processed and presented by antigen presenting cells. In addition, factors leading to the exacerbation of the inflammatory response, the generation of danger signals or oxidative stress, contribute to the development of hypersensitivity reactions through mechanisms not completely understood.
Detoxifying and metabolic enzymes play multiple roles in cell homeostasis and may participate in drug hypersensitivity through various mechanisms. Metabolites produced by drug transformation carried out by these enzymes could activate the immune system. In addition, detoxifying enzymes play important roles in the control of inflammation, cellular redox status, and cytotoxicity.
Inflammation and oxidative stress cooperate in the pathogenesis of allergic diseases. A situation of oxidative stress may concur with sensitization and favor Th2 responses (Utsch et al., ). Moreover, oxidative stress induction is common to chemical allergens, including those that induce type IV hypersensitivity (Corsini et al., ). Indeed, numerous drugs, including doxorubicin, dapsone, cisplatin, sulfamethoxazole, and many others, elicit oxidative stress through multiple mechanisms (Bhaiya et al., ; Deavall et al., ; Hargreaves et al., ), increasing the generation of danger signals that act as coactivators for the allergic reaction (Sanderson et al., ). In turn, oxidative stress can increase the formation of drug-protein adducts by favoring the generation of reactive metabolites of drugs, thus facilitating protein haptenation and subsequent activation of the immune system or other toxic effects. Furthermore, oxidized proteins may be more susceptible to the addition of certain drugs or drug metabolites (Lavergne et al., ). Oxidative stress can also alter the ratio between reduced and oxidized glutathione species by depletion of the reduced form (GSH), thus favoring protein glutathionylation and/or reducing the possibility of drug detoxification through GSH conjugation. Conversely, it has been reported that antioxidants such as N-acetylcysteine, ebselen, and pyrrolidine dithiocarbamate can ameliorate immune and allergic responses in several models (Matsue et al., ; Monick et al., ; Galbiati et al., ). Importantly, a reduced antioxidant or cytoprotective capacity has been evidenced in allergy and asthma (Lutter et al., ), and sensitization to certain allergens is associated with inadequate antioxidant responses. Consequently, it has been proposed that exploring the master regulator of antioxidant responses Nuclear factor erythroid 2-related factor 2 (Nrf-2), may provide novel biomarkers for determining the sensitization potential of several chemicals (Natsch and Emter, ; Ade et al., ).
Recently, we have studied two types of detoxifying enzymes, GST and AKR (Sánchez-Gómez et al., , ; Díez-Dacal et al., ), which interact with several drugs and are important players in the regulation of inflammation and redox status. Indeed, genetic variations in these enzymes have been associated with an increased risk of suffering diseases with an important allergic component such as atopy or asthma. Nevertheless, whereas the role of other drug metabolizing enzymes, such as cytochromes, in drug hypersensitivity has been frequently explored (Gueant et al., ; Bhattacharyya et al., ), those of GST and AKR remain poorly understood. Here, we provide a perspective on the interactions of GSTP1-1 and AKR1B1 with both drugs and factors contributing to allergic reactions, and suggest avenues to assess their potential as drug hypersensitivity biomarkers.
GSTP1-1
Glutathione-S-transferases are phase II enzymes that detoxify numerous endogenous and exogenous compounds by conjugation with GSH (Hayes et al., ). GSH-conjugates can then be exported from cells by the multidrug transporter system (Díez-Dacal and Pérez-Sala, ). Numerous genetic variations in GST enzymes have been identified and their functional consequences have been the subject of previous review (Board and Menon, ). Regarding GSTP1-1, the polymorphisms described have been mostly studied in the context of cancer and drug metabolism. However, in addition to its metabolic function, GSTP1-1 modulates stress response cascades by mechanisms involving protein-protein interactions with signaling proteins, like c-Jun terminal Kinase (JNK) and other mitogen activated protein kinases, Peroxiredoxin 6 (Prdx6), and Tumor necrosis factor (TNF)-associated factor 2 (TRAF2; Adler et al., ; Wu et al., 2006). Moreover, GSTP1-1 facilitates protein glutathionylation, thus regulating protein activity (Tew, ). Therefore, a complex landscape appears in which GSTP1-1 integrates cellular responses to redox stress by catalytic, protein-protein interaction and posttranslational mechanisms (Figure 1).
Figure 1
Interaction of GSTP1-1 with oxidative stress
GSTP1-1 is a key factor for cellular adaptation to oxidative stress at multiple levels. GSTP1-1 expression is strongly induced by oxidative stress as a defense mechanism through the binding of transcription factors, like Nrf-2 and activator protein (AP)-1, to the antioxidant response elements in its promoter (Kawamoto et al., ; Hayes et al., ). In turn, oxidative stress can reversibly inactivate GSTP1-1 by intramolecular disulfide formation or oligomerization (Shen et al., ; Sánchez-Gómez et al., ). Moreover, several electrophilic agents, including endogenous reactive mediators and drugs, induce an irreversible crosslinking of the enzyme (Sánchez-Gómez et al., ). The main residues involved in these modifications are the most reactive cysteines in GSTP1-1, namely, Cys47, and/or Cys101. Both, GSTP1-1 oligomerization and crosslinking affect its interactions with signaling proteins and stress cascades, as mentioned above.
GSTP1-1 can promote the reversible incorporation of GSH (S-glutathionylation) into low pKa cysteine residues of proteins. This modification modulates protein function, but also protects cysteine residues from further irreversible oxidations (Tew, ; Townsend et al., ), allowing the reduced form to be regenerated. Proteins S-glutathionylated by GSTP1-1 include Prdx6 (Manevich and Fisher, ), AKR1B1, and GSTP1-1 itself (Townsend et al., ; Wetzelberger et al., 2010).
Altogether, this evidence illustrates the complex redox regulation of GSTP1-1. Under mild oxidative stress, induction of GSTP1-1 expression and its redox “recycling” function afford cellular protection. However, pharmacological treatments or acute inflammation can inactivate GSTP1-1 either by direct oxidation and/or chemical inhibition. In both cases, allelic variants of GSTP1-1, namely, wild type GSTP1-1 (Ile105, Ala114) and variants: GSTP1-1(Ile105Val, Ala114), GSTP1-1(Ile105Val, Ala114Val), and GSTP1-1(Ile105, Ala114Val), differentially exert protective functions on protein activity and lipid peroxidation, which may influence susceptibility to oxidative stress of subjects carrying the various forms (Manevich et al., ).
Interaction of GSTP1-1 with drugs
GSTP1-1 displays multiple interactions with drugs, either catalyzing their detoxification by GSH conjugation or being inactivated by them. These interactions are crucial for cancer therapy. GSTP1-1 overexpression is an important factor involved in tumor chemoresistance (Díez-Dacal and Pérez-Sala, ), and therefore, an important drug target, for which structurally diverse inhibitors, including ethacrynic acid, glutathione analogs, GSTP1-1 activatable drugs, and natural compounds have been considered (Singh, ). The mechanism of action of these compounds frequently involves binding to cysteine residues and/or GSTP1-1 oligomerization, as it occurs with electrophilic prostaglandins (PGs) or chlorambucil (Sánchez-Gómez et al., ). Interestingly, the pattern of GSTP1-1 crosslinking and/or chemical modifications depends on the presence of both substrates and inhibitors, for which this enzyme can be considered a converging platform for the effects of drugs and danger signals arising from oxidative stress or inflammation (Sánchez-Gómez et al., ).
GSTP1-1 also keeps important direct or indirect interactions with the mechanism of action of drugs such as acetaminophen (McGarry et al., ), acetylsalycilic acid (Baranczyk-Kuzma and Sawicki, ), and other non-steroidal anti-inflammatory drugs (Orhan and Sahin, ). In fact, GSTP1-1 deficiency correlates with higher acetaminophen toxicity in mice (McGarry et al., ). Also, a “ligandin” role of GSTP1-1 should be taken into account, since this abundant cytosolic enzyme can sequester drugs, thus reducing their effective concentrations (Oakley et al., ; Lu and Atkins, ).
Interaction of GSTP1-1 with inflammatory mediators
GSTP1-1 also displays multiple interactions with inflammation: it is induced by proinflammatory stimuli, but this could exert a negative feedback on the inflammatory response. GSTP1-1 ameliorates the inflammatory response in several experimental models of tissue damage or inflammation (Xue et al., 2005; Luo et al., ). Interestingly, several GST, including GSTP1-1, attenuate the action of the inflammatory mediator 15-deoxy-Δ12, 14-PGJ2 (15d-PGJ2; Paumi et al., ). Evidence from our laboratory indicates that overexpression of GSTP1-1 in rat mesangial cells reduces the capacity of 15d-PGJ2 to activate Peroxisome proliferator activated receptor (PPAR) transcription factor(s) (Figure 1). Moreover, a reduction in the basal PPAR activity is also observed, suggesting the inactivation of endogenous PPAR agonists or the participation of additional mechanisms in GSTP1-1 regulation of inflammation.
In turn, electrophilic mediators like 15d-PGJ2 can inhibit GST activity in several cell types through various mechanisms (Sánchez-Gómez et al., ). Interestingly, cyclopentenone prostaglandins (cyPG) with dienone structure induce an extensive intermolecular crosslinking of GSTP1-1 monomers, involving mainly Cys47 and Cys101 (Sánchez-Gómez et al., ) that is blocked by GSH or non-metabolizable GSH analogs, indicating that cyPG-GSTP1-1 interaction is impaired in the GSH-bound enzyme.
Therefore, the interaction of GSTP1-1 with inflammatory mediators like cyPG is a two-way process strongly dependent on GSH availability (Gayarre et al., ; Díez-Dacal and Pérez-Sala, ), since the enzyme can conjugate electrophilic mediators with GSH, whereas cyPG can induce the expression and/or inhibit GST activity in a cell type-dependent manner (Sánchez-Gómez et al., ). Some of these interactions have also been evidenced for other GST isoforms (Gilot et al., ; Kudoh et al., ). These observations illustrate the intricate implications of GST in inflammation, with the net outcome depending on the delicate balance of all these factors.
GSTP1-1 in allergic reactions
Although GST have been mostly studied in the fields of oxidative stress and chemoresistance, an interesting role in allergic reactions is emerging. Endogenous GSTP1-1 is an important target for haptenation, which has been related to the induction of certain drug hypersensitivity reactions (Meng et al., ). In addition, genetic variants of several GST isoforms have been found to associate with allergic processes including asthma (Tamer et al., ), drug eruptions (Ates et al., ), sensitization to thimerosal (Westphal et al., 2000), or allergic rhinitis (Iorio et al., ). In the case of GSTP1-1, both down- and up-regulations of GSTP1-1 levels have been reported in association with asthma (Schroer et al., ): whereas low levels could contribute to asthma, oxidative stress associated with the allergic response could induce GSTP1-1 expression. These changes in expression may in turn be modulated by the occurrence of polymorphisms, like Ile105Val (rs 1695; Dragovic et al., ), since this variant has been reported to display a reduced ability to conjugate several electrophilic drugs and reactive metabolites to GSH, and may associate with certain allergic diseases, including atopy and asthma (Hoskins et al., ). Polymorphic forms of GSTP1-1 correlate with the aggravation of asthma symptoms induced by air pollution (Su et al., ), and increased risk of asthma associated with acetaminophen (Kang et al., ) and exercise (Islam et al., ). In addition, the Ile105 wild type enzyme associates with enhancement of certain nasal allergic responses (Gilliland et al., ), whereas, according to another study, the Ala114 wild type enzyme associates with increased risk of atopy (Schultz et al., ). Nevertheless, lack of association of GSTP1-1 polymorphisms with allergic diseases or drug hypersensitivity has been reported in other studies, potentially due to differences in the genetic backgrounds of the patient cohorts studied.
Altogether, these findings support the role of GSTP1-1 as a risk factor in hypersensitivity responses by multiple mechanisms, given its multifunctional involvement in drug metabolism and inflammation. Moreover, GSTP1-1 emerges as a key factor to be considered in future genomic studies related with allergy development and drug hypersensitivity reactions.
AKR1B1
AKR1B1 (or aldose reductase) is a member of the AKR superfamily, which comprises multiple enzymes involved in oxidoreduction of endogenous and exogenous compounds, including aliphatic and aromatic aldehydes, monosaccharides, steroids, aromatic hydrocarbons (PAHs), or isoflavonoids, using NADH or NADPH as cofactors. Structurally, this phase I metabolizing enzyme (Penning and Drury, ) is folded into a (α/β)8-barrel motif that is highly conserved among the members of this family and harbors the active site at its C-terminal end (Jez et al., ).
AKR1B1 primary role is to afford constitutive and inducible protection against toxic aldehydes generated under oxidative stress (Jin and Penning, ; Lyon et al., ). AKR1B1 reduces highly reactive lipid peroxidation products like 4-hydroxy-2-nonenal (HNE), acrolein, and methylglyoxal, as well as GSH-conjugates of these aldehydes such as glutathionyl-4-hydroxy-2-nonenal (GS-HNE) and GS-acrolein (Kolb et al., ; Srivastava et al., ; Vander Jagt et al., 2001). For instance, AKR1B1 activation played a cardioprotective role in rat myocardial ischemia by decreasing the accumulation of lipid peroxidation products in the ischemic heart (Kaiserova et al., ). Similarly, induction of AKR1B1 expression in response to oxidative stress plays a role in the antioxidant response (Wang et al., 2012). AKR1B1 also participates in steroid hormones catabolism and plays an important role in the regulation of steroid function in several tissues (Barski et al., ).
Nevertheless, AKR1B1 also has a negative side since it can promote tumor chemoresistance and contribute to the perpetuation of inflammation and to the development of secondary diabetic complications (Figure 2).
Figure 2
Interactions of AKR1B1 with oxidative stress
AKR1B1 activity is regulated by oxidative posttranslational modifications. The highly nucleophilic Cys298, located near the active site, can be modified by different reactive species like nitric oxide (NO), HNE, or oxidized glutathione. These modifications may reduce or increase AKR1B1 catalytic activity, depending on the modifying moiety, and reduce its susceptibility to pharmacological inhibitors. Interestingly, NADPH protects Cys298 from modification by these agents (Chandra et al., ; Del Corso et al., ; Petrash, ).
AKR1B1 is a target gene of Nrf-2, the master transcription factor regulating the antioxidant response. Therefore, it is induced by numerous oxidative stimuli and participates in the antioxidant response (Kang et al., ; Wang et al., 2012). In consequence, AKR1B1 expression is increased in tissues with elevated oxidative stress, e.g., in alcoholic liver disease or vascular inflammation (Srivastava et al., ), where in some cases affords a protective role (Kang et al., ). Nevertheless, excessive AKR1B1 activity can lead to NADPH depletion and oxidative stress.
This occurs in diabetes, where AKR1B1 metabolizes excess glucose through the polyol pathway. An increased flux through this pathway can lead to osmotic stress due to the increased formation of sorbitol, as well as to a redox imbalance by the elevated consumption of NADPH (Petrash, ; Figure 2). NADPH is a substrate/cofactor for several enzymes involved in the cellular antioxidant defense, including glutathione reductase (GSH regeneration), peroxiredoxins and thioredoxin, as well as for several detoxifying systems (Pollak et al., ). Therefore, depletion of NADPH changes the NADPH/NADP+ ratio contributing to oxidative stress and reducing the cellular ability to recover after an oxidative insult (Pollak et al., ; Ying, 2008).
Interaction of AKR1B1 with drugs
AKR1B1 is an important drug target due to its implication in the development of diabetic complications. Therefore, the search for inhibitors from both synthetic and natural sources has yielded a wide array of compounds that bind and/or inhibit the enzyme, with structural information on their binding arising from molecular modeling or crystallographic studies. AKR enzymes are involved in chemoresistance because they metabolize carbonyl-containing drugs, including naloxone and ketotifen (Endo et al., ). The anthracycline antibiotics doxorubicin and daunorubicin pose an important case, since they are among the most effective chemotherapic drugs. However, the reduction of their carbonyl group to their corresponding alcohol, yielding doxorubicinol and daunorubicinol, respectively, reduces their efficacy (Veitch et al., 2009). Overexpression of AKR1B1 inactivates these drugs and leads to resistance of various tumor cells (Plebuch et al., ; Heibein et al., ). Conversely, AKR1B1 inhibition increases the cytotoxic effects of the anticancer agents doxorubicin and cisplatin in HeLa cervical carcinoma cells (Lee et al., ), and the AKR inhibitors PGA1 and AD-5467 improve the effectiveness of doxorubicin in lung cancer cells (Díez-Dacal et al., ; Díez-Dacal and Pérez-Sala, ). Natural variants of certain AKR enzymes have been identified that present a reduced capacity to metabolize daunorubicin and doxorubicin in vitro (Bains et al., , ). There is little information on the involvement of AKR1B1 metabolites in hypersensitivity reactions. Nevertheless, daunorubicinol has toxic effects per se because it induces cardiomyopathy (Minotti et al., ).
Interaction of AKR1B1 with inflammatory mediators
AKR1B1 plays an important role in different inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and colon cancer. AKR1B1 can be induced by proinflammatory stimuli (Bresson et al., ). Transcription factors Nuclear factor (NF)-κB and AP-1 activate the AKR1B1 promoter through binding to the osmotic response element (ORE; Iwata et al., ; Lee et al., ) and the phorbol ester response or AP-1 sites, respectively (Penning and Drury, ).
Although AKR1B1 can play a protective role by detoxifying acrolein or HNE, it can also play a positive/amplifying role in inflammation through various mechanisms (Figure 2). In particular, metabolism of HNE or its glutathione conjugate GS-HNE can result in products, such as 1, 4-dihydroxynonene (DHN) and glutathionyl-1,4-dihydroxynonane (GS-DHN), which are still toxic and promote activation of phospholipase C (PLC)-NF-κB cascades perpetuating inflammation (Ramana et al., ; Srivastava et al., ). Thus, inhibition of AKR1B1 reduced NF-κB-dependent inflammatory markers, and the synthesis of TNF-α stimulated by hyperglycemic conditions, and of inflammatory mediators like NO and PGE2 (Ramana and Srivastava, ).
Interestingly, AKR1B1 displays PGF2α synthetizing activity through which it can regulate PGE2 production (Bresson et al., ), thus contributing to the modulation of inflammation. In turn, AKR1B1 can bind several PG, including PGE1 and PGE2 and their cyclopentenone products, PGA1 and PGA2, which results in inhibition of the enzyme (Díez-Dacal et al., ). However, whereas binding and inhibition by PGE appear to be fully reversible, cyPG form a Michael adduct that seems irreversible under certain conditions. Nevertheless, concentrations of GSH in the cellular range (millimolar) elicit a retro-Michael reaction, a fact that contributes to explain the more intense modification and inhibition of some AKRs detected in GSH-depleted cells (Díez-Dacal et al., ).
AKR1B1 in allergic reactions
Early reports linking AKR1B1 to hypersensitivity provided fragmented pieces of evidence. The AKR1B1 inhibitor sorbinil, not currently used in clinical practice, elicited severe adverse effects, including hypersensitivity attributed to protein adducts produced by sorbinil metabolites (Maggs and Park, ). Interestingly, lodoxamide tromethamine, and several anti-allergy drugs, inhibit AKR1B1 (White, 1981), providing additional possibilities of interaction with the hypersensitivity response.
Recent studies using pharmacological or genetic depletion establish a positive role for AKR1B1 in allergy. In mice, AKR1B1 inhibition reduced airway inflammation, hyperresponsiveness and IgE and Th2-cytokine levels in ovalbumin and ragweed pollen extract-induced asthma (Yadav et al., 2009, 2011a). Furthermore, studies in AKR−/− mice also support a role of AKR1B1 in the pathogenesis of asthma and allergic rhinitis (Yadav et al., 2011b, 2013a). Moreover, the efficacy of AKR1B1 inhibitors in mouse models supports their use to treat these allergic conditions (Yadav et al., 2011b, 2013a). In mice sensitized with ovalbumin, AKR1B1 inhibition with fidarestat prevented the airway remodeling observed in chronic asthma by blocking the tumor growth factor β (TGFβ), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Protein kinase B (PKB/AKT)/Glycogen synthase kinase-3 beta (GSK3B) axis (Yadav et al., 2013b).
The mechanisms linking AKR1B1 with allergy are not fully understood. Nevertheless, it could be hypothesized that it provides coactivators of the allergic response through its contribution to oxidative stress or to the generation of proinflammatory mediators, like aldehyde conjugates.
In contrast to the numerous studies on GSTP1-1 polymorphisms in allergic patients, most genetic studies on AKR1B1 have been directed to explore its association with the development of diabetic implications (Demaine, ), and very little information exists on the impact of AKR1B1 variants on drug metabolism or hypersensitivity reactions. Nevertheless, given the fact that an increased glucose flux through the polyol pathway leads to redox imbalance, it would be interesting to assess the involvement of AKR1B1 variants in oxidative stress. In addition, the recent evidences on the involvement of AKR1B1 in allergy grant its study in association with these processes.
In summary, AKR and GST enzymes are emerging as important regulators of the balance of inflammatory mediators. This, together with their association with allergic processes and their ability to metabolize and be covalently modified by drugs makes them attractive candidates to explore their involvement not only in allergy in general but in drug hypersensitivity.
Funding
This work has been supported by grants SAF2012-36519 from MINECO and SAF-2015-68590-R from MINECO/FEDER and ISCIII RETIC RIRAAF RD12/0013/0008 to DP, and RD12/0013/0002 to JA.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Author contributions
FS contributed to manuscript writing, figure preparation and experimental work. BD contributed to manuscript writing and figure preparation. EG contributed to manuscript writing. JA contributed to manuscript writing. MP contributed to manuscript writing. DP coordinated and wrote the manuscript and prepared figures.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AdeN.LeonF.PallardyM.PeifferJ. L.Kerdine-RomerS.TissierM. H.et al. (2009). HMOX1 and NQO1 genes are upregulated in response to contact sensitizers in dendritic cells and THP-1 cell line: role of the Keap1/Nrf2 pathway. Toxicol. Sci.107, 451–460. 10.1093/toxsci/kfn243
2
AdlerV.YinZ.FuchsS. Y.BenezraM.RosarioL.TewK. D.et al. (1999). Regulation of JNK signaling by GSTp. EMBO J. 18, 1321–1334. 10.1093/emboj/18.5.1321
3
AtesN. A.TursenU.TamerL.KanikA.DericiE.ErcanB.et al. (2004). GlutathioneS-transferase polymorphisms in patients with drug eruption. Arch. Dermatol. Res.295, 429–433. 10.1007/s00403-003-0446-z
4
BainsO. S.GrigliattiT. A.ReidR. E.RiggsK. W. (2010). Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J. Pharmacol. Exp. Ther.335, 533–545. 10.1124/jpet.110.173179
5
BainsO. S.TakahashiR. H.PfeiferT. A.GrigliattiT. A.ReidR. E.RiggsK. W. (2008). Twoallelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin. Drug Metab. Dispos.36, 904–910. 10.1124/dmd.107.018895
6
Baranczyk-KuzmaA.SawickiJ. (1997). Biotransformation in monkey brain: coupling of sulfation to glutathione conjugation. Life Sci.61, 1829–1841. 10.1016/S0024-3205(97)00807-2
7
BarskiO. A.TipparajuS. M.BhatnagarA. (2008). Thealdo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab. Rev.40, 553–624. 10.1080/03602530802431439
8
BhaiyaP.RoychowdhuryS.VyasP. M.DollM. A.HeinD. W.SvenssonC. K. (2006). Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts. Toxicol. Appl. Pharmacol.215, 158–167. 10.1016/j.taap.2006.02.006
9
BhattacharyyaS.SinhaK.SilP. C. (2014). Cytochrome P450s: mechanisms and biological implications in drug metabolism and its interaction with oxidative stress. Curr. Drug Metab.15, 719–742. 10.2174/1389200215666141125121659
10
BoardP. G.MenonD. (2013). Glutathione transferases, regulators of cellular metabolism and physiology. Biochim. Biophys. Acta1830, 3267–3288. 10.1016/j.bbagen.2012.11.019
11
BressonE.Lacroix-PepinN.Boucher-KovalikS.ChapdelaineP.FortierM. A. (2012). The Prostaglandin F synthase activity of the human aldose reductase AKR1B1 brings new lenses to look at pathologic conditions. Front. Pharmacol.3:98. 10.3389/fphar.2012.00098
12
ChandraA.SrivastavaS.PetrashJ. M.BhatnagarA.SrivastavaS. K. (1997). Activesite modification of aldose reductase by nitric oxide donors. Biochim. Biophys. Acta1341, 217–222. 10.1016/S0167-4838(97)00084-8
13
CorsiniE.GalbiatiV.NikitovicD.TsatsakisA. M. (2013). Role of oxidative stress in chemical allergens induced skin cells activation. Food Chem. Toxicol.61, 74–81. 10.1016/j.fct.2013.02.038
14
DeavallD. G.MartinE. A.HornerJ. M.RobertsR. (2012). Drug-induced oxidative stress and toxicity. J. Toxicol.2012:645460. 10.1155/2012/645460
15
Del CorsoA.Dal MonteM.VilardoP. G.CecconiI.MoschiniR.BanditelliS.et al. (1998). Site-specific inactivation of aldose reductase by 4-hydroxynonenal. Arch. Biochem. Biophys.350, 245–248. 10.1006/abbi.1997.0488
16
DemaineA. G. (2003). Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr. Med. Chem.10, 1389–1398. 10.2174/0929867033457359
17
Díez-DacalB.GayarreJ.GharbiS.TimmsJ. F.CoderchC.GagoF.et al. (2011). Identificationof aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by PGA1: implications for anti-tumoral activity. Cancer Res.71, 4161–4171. 10.1158/0008-5472.CAN-10-3816
18
Díez-DacalB.Pérez-SalaD. (2010). Anti-inflammatory prostanoids: focus on the interactions between electrophile signalling and resolution of inflammation. ScientificWorldJournal10, 655–675. 10.1100/tsw.2010.69
19
Díez-DacalB.Pérez-SalaD. (2012). A-class prostaglandins: early findings and new perspectives for overcoming tumor chemoresistance. Cancer Lett.320, 150–157. 10.1016/j.canlet.2012.03.003
20
Díez-DacalB.Sánchez-GómezF. J.Sánchez-MurciaP. A.MilackovaI.ZimmermanT.BallekovaJ.et al. (2016). Molecular interactions and implications of aldose reductase inhibition by PGA1 and clinically used prostaglandins. Mol. Pharmacol. 89, 42–52. 10.1124/mol.115.100693
21
DragovicS.VenkataramanH.BegheijnS.VermeulenN. P.CommandeurJ. N. (2014). Effect of human glutathione S-transferase hGSTP1-1 polymorphism on the detoxification of reactive metabolites of clozapine, diclofenac and acetaminophen. Toxicol. Lett.224, 272–281. 10.1016/j.toxlet.2013.10.023
22
EndoS.MatsunagaT.AraiY.IkariA.TajimaK.El-KabbaniO.et al. (2014). Cloning and characterization of four rabbit aldo-keto reductases featuring broad substrate specificity for xenobiotic and endogenous carbonyl compounds: relationship with multiple forms of drug ketone reductases. Drug Metab. Dispos.42, 803–812. 10.1124/dmd.113.056044
23
GalbiatiV.MitjansM.LucchiL.VivianiB.GalliC. L.MarinovichM.et al. (2011). Further development of the NCTC 2544 IL-18 assay to identify in vitro contact allergens. Toxicol. In Vitro25, 724–732. 10.1016/j.tiv.2010.12.011
24
GayarreJ.StamatakisK.RenedoM.Pérez-SalaD. (2005). Differential selectivity of protein modification by the cyclopentenone prostaglandins PGA1 and 15-deoxy-Δ12, 14-PGJ2: role of glutathione. FEBS Lett.579, 5803–5808. 10.1016/j.febslet.2005.09.069
25
GillilandF. D.LiY. F.SaxonA.Diaz-SanchezD. (2004). Effectof glutathione-S-transferase M1 and P1 genotypes on xenobiotic enhancement of allergic responses: randomised, placebo-controlled crossover study. Lancet363, 119–125. 10.1016/S0140-6736(03)15262-2
26
GilotD.LoyerP.CorluA.GlaiseD.Lagadic-GossmannD.AtfiA.et al. (2002). Liver protection from apoptosis requires both blockage of initiator caspase activities and inhibition of ASK1/JNK pathway via glutathione s-transferase regulation. J. Biol. Chem.277, 49220–49229. 10.1074/jbc.M207325200
27
GueantJ. L.Gueant-RodriguezR. M.GastinI. A.Cornejo-GarciaJ. A.ViolaM.BarbaudA.et al. (2008). Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity. Curr. Pharm. Des.14, 2770–2777. 10.2174/138161208786369795
28
HargreavesI. P.Al ShahraniM.WainwrightL.HealesS. J. (2016). Drug-induced mitochondrial toxicity. Drug Saf. 39, 661–674. 10.1007/s40264-016-0417-x
29
HayesJ. D.FlanaganJ. U.JowseyI. R. (2005). Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45, 51–88. 10.1146/annurev.pharmtox.45.120403.095857
30
HeibeinA. D.GuoB.SprowlJ. A.MacLeanD. A.ParissentiA. M. (2012). Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer12:381. 10.1186/1471-2407-12-381
31
HoskinsA.WuP.ReissS.DworskiR. (2013). Glutathione S-transferase P1 Ile105Val polymorphism modulates allergen-induced airway inflammation in human atopic asthmatics in vivo. Clin. Exp. Allergy43, 527–534. 10.1111/cea.12086
32
IorioA.PolimantiR.PiacentiniS.LiumbrunoG. M.ManfellottoD.FuciarelliM. (2014). Deletion polymorphism of GSTT1 gene as protective marker for allergic rhinitis. Clin. Respir. J. 9, 481–486. 10.1111/crj.12170
33
IslamT.BerhaneK.McConnellR.GaudermanW. J.AvolE.PetersJ. M.et al. (2009). Glutathione-S-transferase (GST) P1, GSTM1, exercise, ozone and asthma incidence in school children. Thorax64, 197–202. 10.1136/thx.2008.099366
34
IwataT.MinucciS.McGowanM.CarperD. (1997). Identification of a novel cis-element required for the constitutive activity and osmotic response of the rat aldose reductase promoter. J. Biol. Chem.272, 32500–32506. 10.1074/jbc.272.51.32500
35
JezJ. M.FlynnT. G.PenningT. M. (1997). A new nomenclature for the aldo-keto reductase superfamily. Biochem. Pharmacol.54, 639–647. 10.1016/S0006-2952(97)84253-0
36
JinY.PenningT. M. (2007). Aldo-keto reductases and bioactivation/detoxication. Annu. Rev. Pharmacol. Toxicol.47, 263–292. 10.1146/annurev.pharmtox.47.120505.105337
37
KaiserovaK.TangX. L.SrivastavaS.BhatnagarA. (2008). Role of nitric oxide in regulating aldose reductase activation in the ischemic heart. J. Biol. Chem.283, 9101–9112. 10.1074/jbc.M709671200
38
KangE. S.HwangJ. S.HamS. A.ParkM. H.KimG. H.PaekK. S.et al. (2014). 15-Deoxy-Delta(12,14)-prostaglandin J2 prevents oxidative injury by upregulating the expression of aldose reductase in vascular smooth muscle cells. Free Radic. Res.48, 218–229. 10.3109/10715762.2013.860224
39
KangE. S.WooI. S.KimH. J.EunS. Y.PaekK. S.ChangK. C.et al. (2007). Up-regulation of aldose reductase expression mediated by phosphatidylinositol 3-kinase/Akt and Nrf2 is involved in the protective effect of curcumin against oxidative damage. Free Radic. Biol. Med.43, 535–545. 10.1016/j.freeradbiomed.2007.05.006
40
KangS. H.JungY. H.KimH. Y.SeoJ. H.LeeJ. Y.KwonJ. W.et al. (2013). Effect of paracetamol use on the modification of the development of asthma by reactive oxygen species genes. Ann. Allergy Asthma Immunol.110, 364.e1–369.e1. 10.1016/j.anai.2013.03.008
41
KawamotoY.NakamuraY.NaitoY.ToriiY.KumagaiT.OsawaT.et al. (2000). Cyclopentenone prostaglandins as potential inducers of phase II detoxification enzymes. 15-deoxy-delta(12,14)-prostaglandin j2-induced expression of glutathione S-transferases. J. Biol. Chem.275, 11291–11299. 10.1074/jbc.275.15.11291
42
KolbN. S.HunsakerL. A.Vander JagtD. L. (1994). Aldosereductase-catalyzed reduction of acrolein: implications in cyclophosphamide toxicity. Mol. Pharmacol.45, 797–801.
43
KudohK.UchinamiH.YoshiokaM.SekiE.YamamotoY. (2014). Nrf2 activation protects the liver from ischemia/reperfusion injury in mice. Ann. Surg.260, 118–127. 10.1097/SLA.0000000000000287
44
LavergneS. N.WangH.CallanH. E.ParkB. K.NaisbittD. J. (2009). “Danger” conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells. J. Pharmacol. Exp. Ther.331, 372–381. 10.1124/jpet.109.155374
45
LeeE. K.RegenoldW. T.ShapiroP. (2002). Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anticancer Drugs13, 859–868. 10.1097/00001813-200209000-00012
46
LeeY. S.PaekK. S.KangE. S.JangH. S.KimH. J.KangY. J.et al. (2005). Involvement of nuclear factor kappaB in up-regulation of aldose reductase gene expression by 12-O-tetradecanoylphorbol-13-acetate in HeLa cells. Int. J. Biochem. Cell Biol.37, 2297–2309. 10.1016/j.biocel.2005.04.016
47
LuW. D.AtkinsW. M. (2004). A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry43, 12761–12769. 10.1021/bi049217m
48
LuoL.WangY.FengQ.ZhangH.XueB.ShenJ.et al. (2009). Recombinant protein glutathione S-transferases P1 attenuates inflammation in mice. Mol. Immunol.46, 848–857. 10.1016/j.molimm.2008.09.010
49
LutterR.van LieshoutB.FolisiC. (2015). Reduced antioxidant and cytoprotective capacity in allergy and asthma. Ann. Am. Thorac Soc.12(Suppl. 2) S133–S136. 10.1513/AnnalsATS.201503-176AW
50
LyonR. C.LiD.McGarvieG.EllisE. M. (2013). Aldo-keto reductases mediate constitutive and inducible protection against aldehyde toxicity in human neuroblastoma SH-SY5Y cells. Neurochem. Int.62, 113–121. 10.1016/j.neuint.2012.10.007
51
MaggsJ. L.ParkB. K. (1988). Drug-protein conjugates–XVI. Studies of sorbinil metabolism: formation of 2-hydroxysorbinil and unstable protein conjugates. Biochem. Pharmacol.37, 743–748. 10.1016/0006-2952(88)90149-9
52
ManevichY.FisherA. B. (2005). Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic. Biol. Med.38, 1422–1432. 10.1016/j.freeradbiomed.2005.02.011
53
ManevichY.HutchensS.TewK. D.TownsendD. M. (2013). Allelic variants of glutathione S-transferase P1-1 differentially mediate the peroxidase function of peroxiredoxin VI and alter membrane lipid peroxidation. Free Radic. Biol. Med.54, 62–70. 10.1016/j.freeradbiomed.2012.10.556
54
MatsueH.EdelbaumD.ShalhevetD.MizumotoN.YangC.MummertM. E.et al. (2003). Generation and function of reactive oxygen species in dendritic cells during antigen presentation. J. Immunol.171, 3010–3018. 10.4049/jimmunol.171.6.3010
55
McGarryD. J.ChakravartyP.WolfC. R.HendersonC. J. (2015). Altered protein S-glutathionylation identifies a potential mechanism of resistance to acetaminophen-induced hepatotoxicity. J. Pharmacol. Exp. Ther.355, 137–144. 10.1124/jpet.115.227389
56
MengX.LawrensonA. S.BerryN. G.MaggsJ. L.FrenchN. S.BackD. J.et al. (2014). Abacavir forms novel cross-linking abacavir protein adducts in patients. Chem. Res. Toxicol.27, 524–535. 10.1021/tx400406p
57
MinottiG.MennaP.SalvatorelliE.CairoG.GianniL. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev.56, 185–229. 10.1124/pr.56.2.6
58
MonickM. M.SamavatiL.ButlerN. S.MohningM.PowersL. S.YarovinskyT.et al. (2003). Intracellularthiols contribute to Th2 function via a positive role in IL-4 production. J. Immunol.171, 5107–5115. 10.4049/jimmunol.171.10.5107
59
NatschA.EmterR. (2008). Skinsensitizers induce antioxidant response element dependent genes: application to the in vitro testing of the sensitization potential of chemicals. Toxicol. Sci.102, 110–119. 10.1093/toxsci/kfm259
60
OakleyA. J.Lo BelloM.NuccetelliM.MazzettiA. P.ParkerM. W. (1999). Theligandin (non-substrate) binding site of human Pi class glutathione transferase is located in the electrophile binding site (H-site). J. Mol. Biol.291, 913–926. 10.1006/jmbi.1999.3029
61
OrhanH.SahinG. (2001). In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes. Exp. Toxicol. Pathol.53, 133–140. 10.1078/0940-2993-00179
62
PaumiC. M.SmithermanP. K.TownsendA. J.MorrowC. S. (2004). Glutathione S-Transferases (GSTs) inhibit transcriptional activation by the peroxisomal proliferator-activated receptor γ (PPARγ) ligand, 15-deoxy-Δ12, 14 prostaglandin J2 (15-d-PGJ2). Biochemistry43, 2345–2352. 10.1021/bi035936+
63
PenningT. M.DruryJ. E. (2007). Humanaldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys.464, 241–250. 10.1016/j.abb.2007.04.024
64
PetrashJ. M. (2004). Allin the family: aldose reductase and closely related aldo-keto reductases. Cell. Mol. Life Sci.61, 737–749. 10.1007/s00018-003-3402-3
65
PlebuchM.SoldanM.HungererC.KochL.MaserE. (2007). Increase dresistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett.255, 49–56. 10.1016/j.canlet.2007.03.018
66
PollakN.DolleC.ZieglerM. (2007b). The power to reduce: pyridine nucleotides–small molecules with a multitude of functions. Biochem. J.402, 205–218. 10.1042/BJ20061638
67
PollakN.NiereM.ZieglerM. (2007a). NAD kinase levels control the NADPH concentration in human cells. J. Biol. Chem.282, 33562–33571. 10.1074/jbc.M704442200
68
RamanaK. V.FadlA. A.TammaliR.ReddyA. B.ChopraA. K.SrivastavaS. K. (2006). Aldosereductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages. J. Biol. Chem.281, 33019–33029. 10.1074/jbc.M603819200
69
RamanaK. V.SrivastavaS. K. (2010). Aldosereductase: a novel therapeutic target for inflammatory pathologies. Int. J. Biochem. Cell Biol.42, 17–20. 10.1016/j.biocel.2009.09.009
70
Sánchez-GómezF. J.Díez-DacalB.PajaresM. A.LlorcaO.Pérez-SalaD. (2010). Cyclopentenone prostaglandins with dienone structure promote cross-linking of the chemoresistance-inducing enzyme glutathione transferase P1-1. Mol. Pharmacol.78, 723–733. 10.1124/mol.110.065391
71
Sánchez-GómezF. J.DoradoC. G.AyusoP. J.AgúndezA. G.PajaresM. A.Pérez-SalaD. (2013). Modulation of GSTP1-1 oligomerization by inflammatory mediators and reactive drugs. Inflamm. Allergy Drug Targets12, 162–171. 10.2174/1871528111312030002
72
Sánchez-GómezF. J.GayarreJ.AvellanoM. I.Pérez-SalaD. (2007). Direct evidence for the covalent modification of glutathione-S-transferase P1-1 by electrophilic prostaglandins: implications for enzyme inactivation and cell survival. Arch. Biochem. Biophys.457, 150–159. 10.1016/j.abb.2006.10.032
73
SandersonJ. P.NaisbittD. J.ParkB. K. (2006). Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J.8, E55–E64. 10.1208/aapsj080107
74
SchroerK. T.GibsonA. M.SivaprasadU.BassS. A.EricksenM. B.Wills-KarpM.et al. (2011). Down regulationof glutathione S-transferase pi in asthma contributes to enhanced oxidative stress. J. Allergy Clin. Immunol.128, 539–548. 10.1016/j.jaci.2011.04.018
75
SchultzE. N.DevadasonS. G.KhooS. K.ZhangG.BizzintinoJ. A.MartinA. C.et al. (2010). The role of GSTP1 polymorphisms and tobacco smoke exposure in children with acute asthma. J. Asthma47, 1049–1056. 10.1080/02770903.2010.508856
76
ShenH.TsuchidaS.TamaiK.SatoK. (1993). Identification of cysteine residues involved in disulfide formation in the inactivation of glutathione transferase P-form by hydrogen peroxide. Arch. Biochem. Biophys.300, 137–141. 10.1006/abbi.1993.1019
77
SinghS. (2015). Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Cancer Chemother. Pharmacol.75, 1–15. 10.1007/s00280-014-2566-x
78
SrivastavaS.ChandraA.AnsariN. H.SrivastavaS. K.BhatnagarA. (1998). Identification of cardiac oxidoreductase(s) involved in the metabolism of the lipid peroxidation-derived aldehyde-4-hydroxynonenal. Biochem. J.329(Pt 3), 469–475. 10.1042/bj3290469
79
SrivastavaS. K.RamanaK. V.BhatnagarA. (2005). Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev.26, 380–392. 10.1210/er.2004-0028
80
SrivastavaS. K.YadavU. C.ReddyA. B.SaxenaA.TammaliR.ShoebM.et al. (2011). Aldosereductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem. Biol. Interact.191, 330–338. 10.1016/j.cbi.2011.02.023
81
SuM. W.TsaiC. H.TungK. Y.HwangB. F.LiangP. H.ChiangB. L.et al. (2013). GSTP1 is a hub gene for gene-air pollution interactions on childhood asthma. Allergy68, 1614–1617. 10.1111/all.12298
82
TamerL.CalikogluM.AtesN. A.YildirimH.ErcanB.SaritasE.et al. (2004). Glutathione-S-transferase gene polymorphisms (GSTT1, GSTM1, GSTP1) as increased risk factors for asthma. Respirology9, 493–498. 10.1111/j.1440-1843.2004.00657.x
83
TewK. D. (2007). Redoxin redux: emergent roles for glutathione S-transferase P (GSTP) in regulation of cell signaling and S-glutathionylation. Biochem. Pharmacol.73, 1257–1269. 10.1016/j.bcp.2006.09.027
84
TownsendD. M.ManevichY.HeL.HutchensS.PazolesC. J.TewK. D. (2009). Novel role for glutathione S-transferase pi. Regulator of protein S-Glutathionylation following oxidative and nitrosative stress. J. Biol. Chem.284, 436–445. 10.1074/jbc.M805586200
85
UtschL.FolisiC.AkkerdaasJ. H.LogiantaraA.van de PolM. A.van der ZeeJ. S.et al. (2015). Allergic sensitization is associated with inadequate antioxidant responses in mice and men. Allergy70, 1246–1258. 10.1111/all.12674
86
Vander JagtD. L.HassebrookR. K.HunsakerL. A.BrownW. M.RoyerR. E. (2001). Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications. Chem. Biol. Interact.130–132, 549–562. 10.1016/S0009-2797(00)00298-2
87
VeitchZ. W.GuoB.HembruffS. L.BewickA. J.HeibeinA. D.EngJ.et al. (2009). Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet. Genomics19, 477–488. 10.1097/FPC.0b013e32832c484b
88
WangF.TianF.WhitmanS. A.ZhangD. D.NishinakaT.ZhangN.et al. (2012). Regulation of transforming growth factor beta1-dependent aldose reductase expression by the Nrf2 signal pathway in human mesangial cells. Eur. J. Cell Biol.91, 774–781. 10.1016/j.ejcb.2012.07.004
89
WestphalG. A.SchnuchA.SchulzT. G.ReichK.AbererW.BraschJ.et al. (2000). Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. Int. Arch. Occup. Environ. Health73, 384–388. 10.1007/s004200000159
90
WetzelbergerK.BabaS. P.ThirunavukkarasuM.HoY. S.MaulikN.BarskiO. A.et al. (2010). Postischemic deactivation of cardiac aldose reductase: role of glutathione S-transferase P and glutaredoxin in regeneration of reduced thiols from sulfenic acids. J. Biol. Chem.285, 26135–26148. 10.1074/jbc.M110.146423
91
WhiteG. J. (1981). Inhibition of oxidative enzymes by anti-allergy drugs. Agents Actions11, 503–509. 10.1007/BF02004713
92
WuY.FanY.XueB.LuoL.ShenJ.ZhangS.et al. (2006). Humanglutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals. Oncogene25, 5787–5800. 10.1038/sj.onc.1209576
93
XueB.WuY.YinZ.ZhangH.SunS.YiT.et al. (2005). Regulation of lipopolysaccharide-induced inflammatory response by glutathione S-transferase P1 in RAW264.7 cells. FEBS Lett.579, 4081–4087. 10.1016/j.febslet.2005.06.034
94
YadavU. C.Aguilera-AguirreL.BoldoghI.RamanaK. V.SrivastavaS. K. (2011b). Aldosereductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma. Respir. Res.12:145. 10.1186/1465-9921-12-145
95
YadavU. C.MishraR.Aguilera-AguirreL.SurS.BolodghI.RamanaK. V.et al. (2013a). Prevention of allergic rhinitis by aldose reductase inhibition in a murine model. Inflamm. Allergy Drug Targets12, 178–186. 10.2174/1871528111312030004
96
YadavU. C.NauraA. S.Aguilera-AguirreL.BoldoghI.BoularesH. A.CalhounW. J.et al. (2013b). Aldosereductase inhibition prevents allergic airway remodeling through PI3K/AKT/GSK3beta pathway in mice. PLoS ONE8:e57442. 10.1371/journal.pone.0057442
97
YadavU. C.NauraA. S.Aguilera-AguirreL.RamanaK. V.BoldoghI.SurS.et al. (2009). Aldosereductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice. J. Immunol.183, 4723–4732. 10.4049/jimmunol.0901177
98
YadavU. C.RamanaK. V.SrivastavaS. K. (2011a). Aldosereductase inhibition suppresses airway inflammation. Chem. Biol. Interact.191, 339–345. 10.1016/j.cbi.2011.02.014
99
YingW. (2008). NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid. Redox Signal.10, 179–206. 10.1089/ars.2007.1672
100
ZorrillaS.GarzónB.Pérez-SalaD. (2010). Selective binding of the fluorescent dye 8-anilinonaphthalene-1-sulfonic acid to PPARγ allows ligand identification and characterization. Anal. Biochem.399, 84–92. 10.1016/j.ab.2009.12.021
Summary
Keywords
glutathione transferase, aldose reductase, inflammation, oxidative stress, detoxification, allergy, drug adduct, drug hypersensitivity
Citation
Sánchez-Gómez FJ, Díez-Dacal B, García-Martín E, Agúndez JAG, Pajares MA and Pérez-Sala D (2016) Detoxifying Enzymes at the Cross-Roads of Inflammation, Oxidative Stress, and Drug Hypersensitivity: Role of Glutathione Transferase P1-1 and Aldose Reductase. Front. Pharmacol. 7:237. doi: 10.3389/fphar.2016.00237
Received
26 April 2016
Accepted
21 July 2016
Published
04 August 2016
Volume
7 - 2016
Edited by
Vita Dolzan, University of Ljubljana, Slovenia
Reviewed by
Collet Dandara, University of Cape Town, South Africa; Ann M. Moyer, Mayo Clinic, USA; Emanuela Corsini, University of Milan, Italy
Updates
Copyright
© 2016 Sánchez-Gómez, Díez-Dacal, García-Martín, Agúndez, Pajares and Pérez-Sala.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Dolores Pérez-Sala dperezsala@cib.csic.es
This article was submitted to Pharmacogenetics and Pharmacogenomics, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.